ArticleNeoplasia (New York, N.Y.)2026

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.

Rupesh Paudel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.